Spironolactone for Acne in Adolescents Ages 12 to 17: Off-Label Use Explained

Updated Jan 28, 2025

Image: HealthRX.com clinical image

At a glance

Drug / spironolactone, an aldosterone antagonist and androgen receptor blocker, sold as Aldactone and CaroSpir
FDA-approved indications / hypertension, edema, primary hyperaldosteronism, heart failure; acne is not an approved indication at any age
Population discussed here / post-pubertal females, approximately ages 12 to 17
Typical dose range in practice / 25 to 150 mg orally once daily, occasionally higher
Proposed mechanism / androgen receptor blockade reducing sebaceous gland androgen signaling and sebum output
Time to visible effect / clinicians generally advise 3 to 6 months before judging response
Key monitoring concerns / blood pressure, menstrual cycle changes, and hyperkalemia risk in patients with renal or adrenal disease
Absolute precaution / pregnancy; spironolactone requires pregnancy exclusion and contraceptive counseling in sexually active patients
Guideline context / American Academy of Dermatology acne management guidance (2016) supports spironolactone for females with hormonal acne patterns, without a stated lower age limit
Evidence level / mostly adult randomized trials plus small retrospective adolescent cohorts; no adolescent-specific randomized controlled trial identified

Direct answer

Spironolactone has no FDA approval for acne in adolescents or adults. Its use for hormonal acne in post-pubertal females ages 12 to 17 is an off-label extrapolation of adult trial evidence, supported by dermatology guideline language and a limited number of small observational studies that included adolescent patients. The core clinical question for this age group is not whether spironolactone can reduce hormonally driven acne lesions, adult trial evidence and mechanistic biology make that plausible, but whether the safety monitoring built for adult women transfers cleanly to a developing patient who may still be establishing a regular menstrual cycle and who requires explicit contraceptive planning if sexually active.

What spironolactone is and why it is used off-label for teen acne

Spironolactone is an aldosterone antagonist originally developed for hypertension, heart failure, and conditions of aldosterone excess. At the doses used for acne, it also blocks androgen receptors in sebaceous glands and reduces the hormonal signal that drives sebum production. Because sebum output correlates with acne severity in hormonally mediated acne, an androgen-receptor blocker is mechanistically plausible as an acne treatment. The FDA has never approved spironolactone for acne at any age, so every prescription written for this purpose, in adults or adolescents, is off-label.

Off-label prescribing is legal in the United States. The FDA regulates whether a manufacturer may market a drug for a given indication; it does not restrict a physician's clinical judgment in prescribing an approved drug for an unapproved use when supported by evidence and professional guidance. Off-label prescribing is common across many drug classes, and spironolactone for hormonal acne is one of the better-established examples in dermatology, reflected in professional society guidance discussed below.

The hormonal biology behind adolescent acne

Puberty increases adrenal androgen output (dehydroepiandrosterone sulfate) and gonadal testosterone. Sebaceous gland androgen receptors respond to this increase with greater sebum production, which is a recognized contributor to acne severity in adolescent females. This biological pathway is the rationale for using an androgen-receptor blocker in patients whose acne follows a hormonal pattern: premenstrual flares, jawline and chin distribution, or resistance to standard topical and antibiotic therapy.

What the evidence actually shows in adolescents

No large randomized controlled trial limited to the 12-to-17 age band for spironolactone and acne was identified for this review. The evidence supporting adolescent use is built from two layers, and readers should keep them distinct rather than treating adolescent outcomes as separately proven.

Layer one: adult randomized evidence. Randomized trials in adult women have compared spironolactone against placebo for hormonal or treatment-resistant acne and reported meaningful reductions in inflammatory lesion counts over several months, generally at doses in the 100 to 200 mg per day range. These trials did not enroll patients under 18, so their findings are extrapolated downward by age, with dose adjusted for smaller body size, rather than independently replicated in teenagers.

Layer two: adolescent-inclusive observational data. Several retrospective cohort studies from pediatric or general dermatology practices have included patients as young as 12 to 14 alongside older teens and young adults, generally reporting that a majority of patients show at least moderate improvement in acne severity scores after several months of treatment at doses in the 25 to 150 mg range, with menstrual irregularity and occasional dizziness as the most common reasons for discontinuation. Because this review could not independently verify the specific study identifiers historically cited for these cohorts, exact sample sizes and response percentages are not reproduced here; a clinician relying on a specific published effect size should confirm it directly against the primary literature before quoting it to a patient or family.

Systematic evidence for combined oral contraceptives in acne, a frequently paired therapy, has been reviewed by the Cochrane Collaboration; readers and clinicians can consult the current Cochrane review directly rather than relying on a secondhand percentage. See the Cochrane Database of Systematic Reviews for the current version of this review, since Cochrane periodically updates its reviews and older figures can become outdated.

What guideline bodies say

The American Academy of Dermatology's 2016 acne management guideline supports spironolactone as a treatment option for females with hormonal or treatment-resistant acne, usable as monotherapy or combined with topical agents and, in some cases, oral antibiotics. The guideline does not set an explicit lower age cutoff for adolescents but does not endorse use before puberty. For a post-pubertal adolescent female, the guideline's reasoning parallels its reasoning for adult women; it does not present adolescent-specific trial data as the basis for that position. Clinicians and families should treat this as guideline-level support for an off-label use, not as evidence that adolescent efficacy and safety have been independently studied at the same depth as in adults.

Evidence and transferability map for this age group

Question	What is directly studied in ages 12-17	What is extrapolated from adults	What needs specialist input before prescribing	Outcome to monitor over time
Does spironolactone reduce hormonal acne lesion counts?	Limited: small retrospective cohorts including some adolescents, not a dedicated RCT	Yes: adult placebo-controlled trials show lesion reduction over months	Confirm hormonal pattern (jawline/chin distribution, premenstrual flare) versus other acne subtypes	Lesion count or IGA score at baseline, 3 months, 6 months
What dose is effective and tolerated?	Not independently established; adolescent series report starting low and titrating	Adult dose-response data (typically 100-200 mg) inform titration ceiling	Pediatric or adolescent dermatology consultation for dose above 100-150 mg	Tolerability at each dose step; menstrual and blood pressure changes
Is hyperkalemia a real risk?	Adolescent-specific incidence data are sparse	Adult data in healthy young women without renal disease suggest low routine risk	Nephrology or endocrinology input if renal impairment, adrenal disease, or interacting medications are present	Baseline potassium; repeat only if new risk factor emerges
Does it affect puberty, growth, or the HPA axis?	Not established either way in adolescents at acne-range doses	Adult pharmacology suggests peripheral androgen/aldosterone receptor action predominates over adrenal cortisol suppression at these doses	Endocrinology input if there is any sign of adrenal insufficiency, abnormal growth trajectory, or atypical pubertal timing	Growth parameters and pubertal staging at routine adolescent visits, not acne-specific labs
Is pregnancy risk adequately covered?	Not adolescent-specific; based on general reproductive safety principles and FDA labeling	Adult contraceptive counseling practice applies directly	Confirm sexual activity status confidentially; arrange contraception if indicated	Pregnancy test at baseline if sexually active; reassess at follow-up visits
What happens with long-term or male use?	Not studied in adolescent males for acne; not recommended	Adult data do not support this use either	Not applicable; this use is not supported and should prompt referral to alternative therapy	Not applicable

This map is meant to separate what a clinician can state with direct adolescent evidence from what is being reasonably extrapolated from adult data. Where extrapolation carries meaningful uncertainty, that uncertainty should be part of the informed consent conversation with the patient and guardian, not smoothed over.

Dosing in the 12 to 17 age group

Adolescent dosing generally follows adult dose-escalation patterns, adjusted downward for smaller or lighter patients, rather than a separately validated pediatric dosing schedule.

Starting dose. Clinical practice commonly starts at 25 to 50 mg once daily for several weeks, allowing assessment of blood pressure response and menstrual cycle change before increasing the dose.

Titration. If tolerated and response is insufficient, the dose is typically increased in 25 to 50 mg increments every several weeks, toward a maintenance range of 50 to 150 mg daily. Doses above 150 mg are less common in adolescents and are generally reserved for patients with confirmed hyperandrogenism on laboratory testing, ideally with endocrinology involvement.

Upper range. Adult trials have used up to 200 mg daily. In practice, many adolescent patients reach adequate control at or below 100 mg, and clinicians should weigh whether pushing toward the adult ceiling is warranted given the thinner adolescent-specific safety data at higher doses.

This article does not provide individualized dosing instructions. Dose selection and titration should be made by the prescribing clinician based on the individual patient's response, tolerability, and comorbidities.

Safety profile: what adolescent-relevant data suggests

Hyperkalemia. This is the most serious theoretical risk of spironolactone. In healthy young patients without renal impairment, diabetes, or concurrent use of ACE inhibitors or potassium-sparing agents, the risk appears low based on adult observational data, and some clinicians therefore do not repeat potassium testing routinely after a normal baseline in low-risk patients. Baseline potassium and creatinine before starting therapy remain standard practice at most centers, and any adolescent with renal disease, adrenal disease, or interacting medications should have more active monitoring and specialist input.

Blood pressure. Because spironolactone has antihypertensive and mild diuretic effects, some adolescents, particularly lean or highly active patients, may experience symptomatic hypotension or dizziness on standing. Blood pressure should be checked at baseline and at the first follow-up visit.

Menstrual irregularity. Irregular cycle length or breakthrough spotting is a recognized effect, related to spironolactone's partial progesterone receptor activity. This is one of the more common reasons adolescents discontinue or reduce the dose. Co-prescribing a combined oral contraceptive can address this while also providing contraception.

Breast tenderness. Breast tenderness is reported at higher doses in some patients and often improves with dose reduction rather than requiring full discontinuation.

Adrenal and growth effects. No published adolescent study reviewed here documented adrenal suppression or growth-related effects at the doses used for acne. This is reassuring but reflects an absence of reported harm in a limited evidence base rather than a large, dedicated safety study designed to detect rare long-term effects. Families should understand this distinction: "not documented" is not the same as "proven safe long-term."

Contraindications and precautions specific to this age group

Absolute contraindications

Pregnancy. Spironolactone carries teratogenic risk based on animal data and requires pregnancy to be excluded before starting, per FDA labeling for the drug's approved indications.
Addison's disease or primary adrenal insufficiency.
Severe renal impairment.
Concurrent use of other potassium-sparing agents or substantial potassium supplementation.

Relative contraindications requiring specialist input

Pre-existing menstrual disorders that warrant their own workup before adding a hormonally active medication.
Eating disorders with associated electrolyte disturbance.
Regular NSAID use, which can blunt the diuretic effect and increase potassium.

The contraception conversation. Any sexually active adolescent female of childbearing potential should receive contraceptive counseling before a prescription is written, and pregnancy should be excluded at baseline. A combined oral contraceptive is a common co-prescription because it can reduce menstrual irregularity from spironolactone while providing contraception; the FDA has approved specific combined oral contraceptive formulations for acne, which is a materially different regulatory status than spironolactone's off-label use. See the FDA drug label database for the current label of any specific product being considered.

Monitoring protocol for adolescent patients

Monitoring practices vary by center; the following reflects a reasonable, guideline-informed approach rather than a single mandated protocol.

Before starting

Serum potassium and creatinine
Blood pressure
Pregnancy test if sexually active
Documentation of baseline menstrual pattern

At the first follow-up (several weeks in)

Blood pressure recheck
Review of menstrual changes and overall tolerability
Repeat potassium generally not needed in a healthy patient with a normal baseline and no new risk factors

At 3 to 6 months

Acne severity reassessment (lesion count or IGA-type scale)
Blood pressure
Potassium only if a new risk factor has emerged, such as new NSAID use, new renal symptoms, or a new interacting medication

Ongoing

Periodic reassessment of whether the indication, dose, and duration remain appropriate
Consideration of whether isotretinoin, a combined oral contraceptive, or another approach should replace or supplement spironolactone

Where spironolactone fits in the adolescent acne treatment algorithm

Spironolactone is not a first-line agent for all adolescent acne. It becomes clinically relevant under fairly specific conditions:

Acne that flares predictably before menstruation
Acne concentrated on the lower face, jawline, and chin, a pattern often associated with androgen-driven disease
Failure of an adequate trial of topical therapy (benzoyl peroxide, a topical retinoid) or oral antibiotics
A preference to avoid isotretinoin, or a bridge while an isotretinoin candidacy workup is underway

Combination therapy. Spironolactone is often combined with a topical retinoid to address comedonal acne while the oral agent targets the hormonal and inflammatory component. Combining with a combined oral contraceptive that carries an FDA-approved acne indication addresses two mechanisms at once and is a well-established pattern in adult dermatology, extrapolated to adolescents by many prescribers.

Where it does not belong. Spironolactone is not appropriate for adolescent males. Androgen blockade in a developing male risks feminizing effects, including gynecomastia and disruption of normal pubertal development. No guideline reviewed here recommends it for male patients with acne at any age.

Spironolactone versus alternatives in adolescent females

Therapy	Evidence base in adolescents	Key advantage	Key limitation
Spironolactone 25-150 mg	Small retrospective cohorts plus adult trial extrapolation; no dedicated adolescent RCT identified	Directly targets androgen-driven acne	Off-label; requires pregnancy precaution; long-term adolescent safety data are limited
Combined oral contraceptive with FDA acne indication	FDA-approved for acne in appropriate candidates	Dual acne treatment and contraception	Not suitable for all patients; carries its own risks (e.g., thromboembolism) that require individual assessment
Oral doxycycline	Established use in adolescent acne	Familiar first-line escalation option	Not hormonal in mechanism; antibiotic stewardship concerns with prolonged use
Isotretinoin	Strong evidence base; regulated through a risk mitigation program	Potential for durable remission	Requires program enrollment, teratogenicity precautions, and monitoring
Topical retinoids	Strong first-line evidence	Low systemic risk	Limited effect on hormonally driven or severe inflammatory acne alone

Because this use is off-label, documenting the clinical rationale is good practice. A thorough chart note typically includes: baseline acne severity and distribution pattern, prior treatments tried and their duration, an explicit off-label disclosure discussion with the patient and guardian, pregnancy status and contraceptive plan if applicable, the specific risks discussed (hyperkalemia, hypotension, menstrual changes, teratogenic risk), and the agreed monitoring schedule.

Professional endocrinology guidance on androgen excess conditions generally supports anti-androgen therapy, including spironolactone, in adolescent females with confirmed hyperandrogenism and associated skin findings when other treatments have not worked. Readers should treat this as guideline-level support requiring the treating clinician's own confirmation of the current guideline text, since specific guideline citations in earlier drafts of this material could not be independently verified for this review.

Evidence boundary: what is established, what is plausible, what is not established

Established. Spironolactone has no FDA approval for acne at any age; its acne use is off-label for adults and adolescents alike. Its mechanism of androgen receptor blockade is well described pharmacologically. Adult randomized trials support efficacy for hormonal acne in women. Pregnancy is a clear precaution requiring exclusion and, where relevant, contraception.

Plausible but not independently proven in adolescents. That adult efficacy and the adult-derived monitoring approach (routine potassium testing largely unnecessary in low-risk healthy patients) transfer cleanly to a 12-to-17-year-old population. That the dose-response relationship seen in adult trials applies proportionally to smaller, still-developing patients.

Not established. Long-term effects of years of use during puberty on growth, adrenal function, or fertility; a validated adolescent-specific dosing protocol; and precise adolescent response rates, since this review could not verify the specific study data historically cited for those figures. Any clinician or family relying on a specific numeric response rate for adolescents should ask the prescriber to point to the primary study directly rather than accepting a secondhand statistic.

A general starting approach some clinicians use (not individualized dosing advice)

For illustration only, and not as a substitute for individualized clinical judgment: a post-pubertal adolescent female with a hormonal acne pattern who has already failed an adequate trial of topical therapy might undergo baseline potassium, creatinine, blood pressure, and pregnancy testing if sexually active; receive counseling on off-label status, teratogenic risk, and the monitoring plan; start at a low dose with food; continue topical therapy in parallel; and be reassessed for tolerability and early response at the first follow-up, with dose titration and a longer-term severity reassessment thereafter. The specific dose, titration pace, and duration of any trial before declaring it inadequate should be determined by the prescribing clinician for the individual patient.

Frequently asked questions

Is spironolactone FDA-approved for acne in teenagers?

No. Spironolactone's FDA-approved indications are hypertension, edema, primary hyperaldosteronism, and heart failure. Acne is not an approved indication at any age, so its use for hormonal acne in adolescents is off-label. Off-label prescribing is legal and is supported for this use by dermatology professional guidance for females with hormonal acne patterns.

At what age can a girl start spironolactone for acne?

Most prescribers restrict spironolactone for acne to post-pubertal females, generally meaning a patient who has begun menstruating and shows physical signs of puberty. Pre-pubertal use is not supported by published evidence. There is no formally validated minimum age within the adolescent range; the decision depends on pubertal status, acne pattern, and prior treatment history, made individually with a clinician.

How long does spironolactone take to work for teenage acne?

Clinicians generally advise waiting at least 3 months to judge early response and up to 6 months for a fuller assessment before concluding the treatment has failed. This timeline is drawn from adult trial data and observational adolescent series; a dedicated adolescent trial with a formally established response timeline was not identified for this review.

What dose of spironolactone is typically used for acne in a teenager?

Practice commonly starts at 25 to 50 mg daily with titration toward 100 to 150 mg if needed and tolerated. There is no independently validated adolescent dosing protocol; doses are extrapolated from adult trial ranges adjusted for the individual patient. The prescribing clinician determines the specific dose and pace of any increase.

Does a teenager need contraception while taking spironolactone?

Sexually active adolescent females should have contraceptive counseling and pregnancy exclusion before starting, because spironolactone carries a teratogenic risk in animal data and pregnancy must be ruled out per its FDA labeling for approved uses. For patients who are not sexually active, contraception is not mandatory, but baseline pregnancy testing is still common practice at many centers. A combined oral contraceptive is often co-prescribed because it can also reduce spironolactone-related menstrual irregularity.

Can boys take spironolactone for acne?

No. Spironolactone can cause feminizing effects in males, including gynecomastia, and can interfere with normal pubertal development. No professional guideline reviewed here supports its use for acne in male patients of any age. Topical retinoids, oral antibiotics, or isotretinoin are the typical escalation path for adolescent males.

Is spironolactone safe for a young teenager with acne?

Short-term observational data in post-pubertal adolescent females suggest an acceptable safety profile at commonly used doses, with blood pressure changes and menstrual irregularity being the main issues to watch for and hyperkalemia being uncommon in healthy patients without renal disease. Long-term safety data specific to adolescents remain limited, and this should be part of the informed consent conversation rather than treated as a settled point.

What blood tests are needed before starting spironolactone in a teenager?

Standard baseline testing includes serum potassium, serum creatinine, and a pregnancy test if the patient is sexually active. Blood pressure should also be measured. Routine repeat potassium testing in a healthy adolescent with a normal baseline and no new risk factors is not universally considered necessary, based on adult observational data, though practice varies by center.

Does spironolactone affect puberty or growth in adolescents?

No study reviewed here documented growth or adrenal suppression effects at the doses used for acne. This reflects an absence of reported harm in a limited evidence base rather than a large study specifically designed to detect rare long-term effects, so it should be described as reassuring rather than proven safe over many years of use.

Can spironolactone be used with birth control pills for teen acne?

Yes, this combination is common in practice. A combined oral contraceptive with an FDA-approved acne indication can address the androgen driver through a different mechanism, reduce spironolactone-related menstrual irregularity, and provide contraception. This pairing is established in adult dermatology practice and extrapolated to adolescents by many prescribers, rather than separately proven in a dedicated adolescent trial.

What happens if a teenager stops spironolactone for acne?

Acne commonly returns after stopping, since spironolactone suppresses the hormonal driver of sebum production rather than permanently altering the sebaceous gland. Patients who achieve clearance and wish to stop should discuss a taper and a follow-up plan with their prescriber rather than stopping abruptly without guidance.

Is spironolactone better than isotretinoin for teenage girls with hormonal acne?

They work differently. Isotretinoin reduces sebaceous gland size and can produce durable remission in many patients, but requires a regulated risk mitigation program due to teratogenicity. Spironolactone reduces androgen signaling without permanently altering the sebaceous gland, so acne often returns after stopping it. For severe nodular or scarring acne, isotretinoin is generally the more definitive option; spironolactone is more often used for moderate, hormonally patterned acne, or while isotretinoin candidacy is being evaluated.

References

U.S. Food and Drug Administration, drug label database (verify current Aldactone and any combined oral contraceptive product label directly): https://www.accessdata.fda.gov/scripts/cder/daf/
Cochrane Database of Systematic Reviews, combined oral contraceptives and acne (confirm current review version before citing an effect size): https://www.cochranelibrary.com/

Note to editorial and medical reviewer: Several study-level claims in the original draft (specific sample sizes, percentage response rates, an attributed guideline quotation, and named trials such as "SAHA trial" and specific JAMA/Pediatric Dermatology cohort figures) could not be verified against a confirmed primary source during this revision and have been converted to general, hedged statements or removed. Before publication, please confirm the American Academy of Dermatology 2016 guideline language directly, and if a specific adolescent cohort study is intended to be cited, retrieve and verify the exact paper before restoring a precise number or quotation.